

### **Amendments to the Claims**

This listing of claims will replace all prior versions, and listings, of claims in the Application:

- 1-25. (Canceled)
26. (New) A method of inhibiting viral infection in a human patient comprising administering to said patient a leflunomide product in an amount effective to inhibit viral virion assembly.
27. (New) The method of claim 26 wherein the leflunomide product is N-(4-trifluoromethylphenyl)-5-methylisoxazol-4-carboxamide (HWA 486).
28. (New) The method of claim 26 wherein the leflunomide product is N-(4-trifluoromethylphenyl)-2-cyano-3-hydroxycrotonamide (A771726).
29. (New) The method of claim 25 wherein the human patient is virally infected.
30. (New) The method of claim 26 wherein the virus is a herpesvirus.
31. (New) The method of claim 26 wherein the virus is selected from the group consisting of paramyxoviruses, picornaviruses and hepatitis viruses.
32. (New) The method of claim 26 wherein the virus is selected from the group consisting of CMV, HSV, measles virus, rhinoviruses, hepatitis B and hepatitis C.
33. (New) The method of claim 26 wherein the virus is resistant to anti-viral agents that inhibit viral DNA replication.
34. (New) The method of claim 26 further comprising administering a pyrimidine compound in an amount effective to enhance serum levels of uridine, cytidine or thymidine.